Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

SAN DIEGO and SHANGHAI, June 9, 2022 /PRNewswire/ — Degron Therapeutics (“Degron”), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets, today announced it has closed a $22 million Series A financing round led by Med-Fine…

Click here to view original post